Literature DB >> 22688820

CMV retinopathy in the antiretroviral therapy era: prevention, diagnosis, and management.

Lisa Barrett1, Sharon Walmsley.   

Abstract

Before the advent of antiretroviral therapy (ART), CMV retinitis was a common, debilitating opportunistic infection in the HIV-infected population. ART has had such a favorable impact on the prevention and management of CMV retinitis that it can be considered in some ways to be CMV therapy. Currently available CMV directed antiviral therapies are quite successful at limiting vision loss, but in resource limited settings there is still significant morbidity associated with the disease. This review summarizes the pathology, diagnosis, clinical course and treatment of retinitis in the pre-ART era to provide context for the contemporary clinical scenario, and highlights current management strategies. Important questions concerning host correlates of susceptibility and ideal therapy in the context of drug resistance are also briefly reviewed.

Entities:  

Year:  2012        PMID: 22688820     DOI: 10.1007/s11908-012-0269-1

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  66 in total

1.  Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group.

Authors:  D F Martin; B D Kuppermann; R A Wolitz; A G Palestine; H Li; C A Robinson
Journal:  N Engl J Med       Date:  1999-04-08       Impact factor: 91.245

2.  Cytomegalovirus retinitis and the acquired immunodeficiency syndrome--bench to bedside: LXVII Edward Jackson Memorial Lecture.

Authors:  Douglas A Jabs
Journal:  Am J Ophthalmol       Date:  2010-12-18       Impact factor: 5.258

3.  Extensive retinal neovascularization as a late finding in human immunodeficiency virus-infected patients with immune recovery uveitis.

Authors:  Mary E Wright; Daniel L Suzman; Karl G Csaky; Henry Masur; Michael A Polis; Michael R Robinson
Journal:  Clin Infect Dis       Date:  2003-04-03       Impact factor: 9.079

4.  The safety of discontinuation of maintenance therapy for cytomegalovirus (CMV) retinitis and incidence of immune recovery uveitis following potent antiretroviral therapy.

Authors:  D A Wohl; M A Kendall; S Owens; G Holland; M Nokta; S A Spector; R Schrier; S Fiscus; M Davis; M A Jacobson; J S Currier; K Squires; B Alston-Smith; J Andersen; W R Freeman; M Higgins; F J Torriani
Journal:  HIV Clin Trials       Date:  2005 May-Jun

5.  Treatment of relapsed cytomegalovirus retinitis with the sustained-release ganciclovir implant.

Authors:  M P Hatton; J S Duker; E Reichel; M G Morley; C A Puliafito
Journal:  Retina       Date:  1998       Impact factor: 4.256

6.  Immune recovery uveitis in AIDS patients with cytomegalovirus retinitis treated with highly active antiretroviral therapy in Venezuela.

Authors:  J Fernando Arevalo; Aristides J Mendoza; Yolanda Ferretti
Journal:  Retina       Date:  2003-08       Impact factor: 4.256

7.  Optimal management of cytomegalovirus retinitis in patients with AIDS.

Authors:  Michael W Stewart
Journal:  Clin Ophthalmol       Date:  2010-04-26

8.  Prevalence of human cytomegalovirus infection in pregnant and non-pregnant women.

Authors:  L C Spano; J Gatti; J P Nascimento; J P G Leite
Journal:  J Infect       Date:  2004-04       Impact factor: 6.072

9.  Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy.

Authors:  Jane R Deayton; Caroline A Prof Sabin; Margaret A Johnson; Vincent C Emery; Pauline Wilson; Paul D Griffiths
Journal:  Lancet       Date:  2004-06-26       Impact factor: 79.321

10.  Prevalence of cytomegalovirus antibody in hemophiliacs and homosexuals infected with human immunodeficiency virus type 1.

Authors:  J B Jackson; A Erice; J A Englund; J R Edson; H H Balfour
Journal:  Transfusion       Date:  1988 Mar-Apr       Impact factor: 3.157

View more
  7 in total

1.  Self-boosting vaccines and their implications for herd immunity.

Authors:  Nimalan Arinaminpathy; Jennie S Lavine; Bryan T Grenfell
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-19       Impact factor: 11.205

Review 2.  Role of the immune system in HIV-associated neuroinflammation and neurocognitive implications.

Authors:  Suzi Hong; William A Banks
Journal:  Brain Behav Immun       Date:  2014-10-22       Impact factor: 7.217

3.  Rationally designed chemokine-based toxin targeting the viral G protein-coupled receptor US28 potently inhibits cytomegalovirus infection in vivo.

Authors:  Katja Spiess; Mads G Jeppesen; Mikkel Malmgaard-Clausen; Karen Krzywkowski; Kalpana Dulal; Tong Cheng; Gertrud M Hjortø; Olav Larsen; John S Burg; Michael A Jarvis; K Christopher Garcia; Hua Zhu; Thomas N Kledal; Mette M Rosenkilde
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-15       Impact factor: 11.205

Review 4.  Ocular involvement in primary immunodeficiency diseases.

Authors:  Sima Hosseinverdi; Hassan Hashemi; Asghar Aghamohammadi; Hans D Ochs; Nima Rezaei
Journal:  J Clin Immunol       Date:  2013-11-30       Impact factor: 8.542

5.  Post-CD19 Chimeric Antigen Receptor T-Cell Therapy Cytomegalovirus Retinitis.

Authors:  Haifa Bin Dokhi; Amjad O Alharbi; Nida H Ibnouf; Bader Alahmari; Mohammed N Refka
Journal:  Cureus       Date:  2022-03-09

6.  Cytomegalovirus retinitis and antiretroviral treatment: A fifteen year experience.

Authors:  Serisha Jay Narain; Linda Visser; Wilbert Sibanda
Journal:  South Afr J HIV Med       Date:  2022-03-08       Impact factor: 2.744

Review 7.  CMV-Specific CD8 T Cell Differentiation and Localization: Implications for Adoptive Therapies.

Authors:  Corinne J Smith; Michael Quinn; Christopher M Snyder
Journal:  Front Immunol       Date:  2016-09-15       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.